Progressive, largely irreversible airflow limitation from chronic bronchitis and/or emphysema.
Also known as: COPD, emphysema, chronic bronchitis, AECOPD, chronic obstructive lung disease
Overview
Heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea, cough, sputum, exacerbations) due to abnormalities of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive airflow obstruction (post-bronchodilator FEV1/FVC <0.7).
Epidemiology
Third leading cause of death worldwide. ~16 million diagnosed in the US; many more undiagnosed. Smoking accounts for ~80% of cases in high-income countries; biomass fuel exposure dominates in low-income settings.
Try two board-style Chronic Obstructive Pulmonary Disease questions
Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.
Question 1PulmonaryMedium
A 45-year-old man with chronic obstructive pulmonary disease (COPD) reports two exacerbations in the past year, one of which required an emergency visit. He uses a short-acting bronchodilator only as needed but remains symptomatic with exertional dyspnea, and he continues to smoke. Post-bronchodilator spirometry shows an FEV1 of 55% predicted, and the blood eosinophil count is 120 cells/uL. Which of the following inhaler regimens is the most appropriate initial maintenance therapy?
ALABA monotherapy
BLAMA + LABA + ICS
CICS monotherapy
DLAMA + LABA
ELAMA monotherapy
Reveal answer & full explanation
Correct answer: D — LAMA + LABA
ALABA monotherapy
BLAMA + LABA + ICS
CICS monotherapy
DLAMA + LABA✓
ELAMA monotherapy
Why LAMA + LABA is correct
This patient meets GOLD Group E criteria (two exacerbations in the past year, including one requiring an emergency visit), which defines high future-exacerbation risk
Per current GOLD guidance, the preferred initial maintenance therapy for Group E is dual long-acting bronchodilation with a long-acting muscarinic antagonist (LAMA) plus a long-acting beta-agonist (LABA)
A blood eosinophil count below 300 cells/uL argues against starting an inhaled corticosteroid (ICS), which is added mainly when eosinophils are 300 cells/uL or higher or when exacerbations persist on dual bronchodilators with eosinophils of 100 cells/uL or higher
Why the others are wrong
LAMA + LABA + ICS — triple therapy is an escalation step (or initial therapy only when eosinophils are at least 300 cells/uL); with eosinophils of 120 cells/uL it is not the appropriate starting regimen (right-diagnosis-wrong-step)
LAMA monotherapy — a single long-acting bronchodilator is maintenance therapy, but GOLD favors dual LAMA plus LABA over either agent by itself in Group E because the combination produces greater symptom relief and fewer exacerbations (right-category-wrong-intensity)
ICS monotherapy — an inhaled corticosteroid without a bronchodilator backbone is not recommended at any stage of COPD and increases pneumonia risk (confused with first-line asthma management)
LABA monotherapy — stepping up from an as-needed short-acting bronchodilator to a long-acting beta-agonist seems natural, and unlike in asthma a LABA without an ICS is acceptable in COPD, but with two exacerbations in the past year he is in Group E, where GOLD recommends starting dual LAMA plus LABA; even as single-agent therapy, a LAMA reduces exacerbations more than a LABA (anchoring on his rescue drug class)
Question 2PulmonaryEasy
A 28-year-old non-smoking woman has progressive dyspnea, FEV1 38% predicted, and lower-lobe-predominant emphysema on CT. Her mother and brother have similar early-onset symptoms. Which of the following is the most likely diagnosis?
Alpha-1 antitrypsin deficiency (AATD) is an autosomal recessive condition (Pi ZZ phenotype).
It causes early-onset emphysema (before age 45) in nonsmokers with lower-lobe predominance.
It also causes liver cirrhosis.
Treatment includes alpha-1 antitrypsin (AAT) augmentation therapy.
Why the others are wrong
Early-onset chronic obstructive pulmonary disease — would be unusual in a lifelong nonsmoker and does not explain the familial, lower-lobe-predominant emphysema; AATD must be excluded first
Lymphangioleiomyomatosis — causes diffuse thin-walled cysts in women of childbearing age, not lower-lobe panacinar emphysema with this inheritance pattern
Primary ciliary dyskinesia — impaired mucociliary clearance produces chronic sinusitis, otitis, and bronchiectasis with obstruction, but the CT shows emphysematous destruction rather than dilated thick-walled airways
Severe persistent asthma — a young nonsmoker with severe airflow obstruction and affected relatives suggests familial asthma, and AATD is often misdiagnosed as asthma for years, but asthma causes bronchial wall thickening and air trapping rather than emphysematous destruction on CT; emphysema in a young nonsmoker with this family history calls for AATD testing
That's 2. Get 7,700+ more.
Unlock the full FirstPassPA bank: 7,700+ board-style questions, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.
You've read your 2 free diagnosis previews. Create your free account to unlock the full Chronic Obstructive Pulmonary Disease (COPD) outline — plus all 514 diagnoses, 7,700+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Progressive exertional dyspnea graded by the mMRC scale: 0 = only with strenuous exercise; 1 = when hurrying or walking up a slight hill; 2 = walks slower than peers or stops for breath at own pace on level ground; 3 = stops for breath after about 100 m or a few minutes on level ground; 4 = too breathless to leave the house or breathless when dressing (mMRC ≥2 = high symptom burden)
Wheezing, chest tightness
Frequent respiratory infections, exacerbations
Signs / physical exam
Barrel chest, hyperresonance to percussion, decreased breath sounds, prolonged expiration
Pursed-lip breathing, tripod position, use of accessory muscles
Idiopathic pulmonary fibrosis — Restrictive pattern on PFTs, dry cough, bibasilar Velcro crackles, honeycombing on HRCT
Alpha-1 antitrypsin deficiency — Premature emphysema (<45 years), basal-predominant on CT, family history; serum AAT level <11 µM
Constrictive (obliterative) bronchiolitis — Post-transplant, post-viral, or connective tissue disease; mosaic attenuation on expiratory CT
Diagnostic workup
Diagnostic criteria
GOLD 2026: symptoms + risk factor exposure + post-bronchodilator FEV1/FVC <0.7. Severity by FEV1 % predicted; clinical group for initial (treatment-naive) therapy by exacerbations in the past 12 months and symptoms: E = ≥1 moderate or severe exacerbation; A = no exacerbations with mMRC 0-1 and CAT <10; B = no exacerbations with mMRC ≥2 or CAT ≥10.
Labs
Alpha-1 antitrypsin level (once per lifetime, all COPD patients per GOLD)
ABG if severe disease or exacerbation (hypoxia, hypercapnia): pH <7.35 with high PaCO2 signals acute or acute-on-chronic hypercapnic failure, whereas chronic CO2 retainers have a near-normal pH with elevated bicarbonate
CBC (polycythemia from chronic hypoxia; eosinophilia ≥300 informs ICS use)
Imaging
CXR — hyperinflation (flattened diaphragms, >10 posterior or >6 anterior ribs visible), increased AP diameter, bullae
CT chest — emphysema pattern (centrilobular, panlobular, paraseptal), exclude lung cancer; required for lung volume reduction or transplant evaluation
ECG — right axis deviation, P pulmonale, multifocal atrial tachycardia
flowchart TD
A[Suspect COPD<br/>dyspnea, cough, risk factors] --> B[Post-bronchodilator<br/>spirometry]
B --> C{FEV1/FVC<br/>< 0.7?}
C -->|No| D[Consider alternative<br/>diagnosis]
C -->|Yes| E[COPD confirmed]
E --> F[Assess symptoms<br/>mMRC, CAT]
E --> G[Assess exacerbations<br/>past 12 months]
F --> H{GOLD Group}
G --> H
H -->|Group A| I[SABA/SAMA<br/>or single LA bronchodilator]
H -->|Group B| J[LABA + LAMA]
H -->|Group E| K[LABA + LAMA<br/>+ ICS if eos ≥300]
GOLD 2026 diagnosis and initial pharmacologic treatment algorithm (treatment-naive patients).
Treatment
First-line
Smoking cessation — single most important intervention; reduces rate of FEV1 decline
Pulmonary rehabilitation for mMRC ≥2 or after exacerbation — the best-evidenced intervention for improving dyspnea, exercise capacity and quality of life
Vaccinations: annual influenza, pneumococcal (PCV20 or PCV21 alone, or PCV15 followed by PPSV23), COVID-19, RSV (single dose, age ≥50), Tdap, recombinant zoster (age ≥50)
GOLD Group A (low symptoms, low exacerbation risk): bronchodilator — short- or long-acting
GOLD Group B (no exacerbations; mMRC ≥2 or CAT ≥10): LABA + LAMA combination
GOLD Group E (≥1 moderate or severe exacerbation in the past 12 months): LABA + LAMA; add ICS if blood eosinophils ≥300 or asthma overlap
Inhaled corticosteroid (ICS): fluticasone, budesonide, mometasone (use only in combination, not monotherapy)
Second-line / adjunct
Triple inhaler (ICS-LABA-LAMA) — fluticasone/umeclidinium/vilanterol or budesonide/glycopyrrolate/formoterol — for exacerbations on LABA + LAMA with eosinophils ≥100; a patient exacerbating on a single long-acting bronchodilator steps up to LABA + LAMA if eosinophils <300 or directly to LABA + LAMA + ICS if ≥300
Roflumilast (PDE4 inhibitor) for severe chronic bronchitis with frequent exacerbations
Azithromycin 250 mg daily or 500 mg 3×/week for exacerbation prevention in select patients
Long-term oxygen therapy if resting SpO2 ≤88% or PaO2 ≤55 mmHg (or ≤59 with cor pulmonale/erythrocytosis) — proven to reduce mortality
Lung volume reduction surgery or bronchoscopic valves for severe upper-lobe emphysema
Lung transplantation for end-stage disease
Acute exacerbation (AECOPD): nebulized SABA + SAMA (albuterol-ipratropium), prednisone 40 mg × 5 days (REDUCE trial), antibiotics if increased sputum purulence (azithromycin, doxycycline, amoxicillin-clavulanate), controlled oxygen to SpO2 88-92%, NIV (BiPAP) for hypercapnic respiratory failure
Long-term home (nocturnal) NIV for persistent daytime hypercapnia (PaCO2 >53 mmHg) 2-4 weeks after recovery from a hypercapnic exacerbation — prolongs time to readmission or death (HOT-HMV)
Complications
Acute exacerbations (viral, bacterial — H. influenzae, S. pneumoniae, M. catarrhalis; Pseudomonas in severe)
Cor pulmonale, pulmonary hypertension
Spontaneous pneumothorax (bullae rupture)
Lung cancer (shared smoking risk; screen with low-dose CT in eligible)
Interventions shown to reduce mortality in COPD (GOLD 2026): smoking cessation, long-term oxygen for severe resting hypoxemia, home NIV for marked persistent hypercapnia, pulmonary rehabilitation started during or within 4 weeks after an exacerbation hospitalization, lung volume reduction surgery in selected upper-lobe emphysema with low exercise capacity, and single-inhaler triple therapy in patients with frequent or severe exacerbations. Smoking cessation is the only intervention proven to slow FEV1 decline.
Check Alpha-1 antitrypsin level once in every COPD patient per GOLD — especially if <45, non-smoker, or basal-predominant emphysema.
Target SpO2 88-92% in AECOPD — over-oxygenation raises PaCO2 mainly by reversing hypoxic pulmonary vasoconstriction (worse V/Q matching, more dead space) and by the Haldane effect; blunted hypoxic drive plays only a minor role.
BiPAP reduces intubation and mortality in hypercapnic AECOPD; consider when pH <7.35 with hypercapnia. Intubate if NIV fails (worsening acidosis or mental status after a 1-2 h trial), NIV is not tolerated, or the patient cannot protect the airway, has copious secretions, or is hemodynamically unstable.
Blood eosinophil count guides ICS use: ≥300 cells/µL favors ICS addition; <100 predicts no benefit and higher pneumonia risk.
References
GOLD 2026 — Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Prevention, Diagnosis and Management of COPD: 2026 Report
REDUCE Trial — Short-Term vs Conventional Glucocorticoid Therapy in AECOPD (Leuppi et al., JAMA 2013)
NETT Trial — National Emphysema Treatment Trial — Lung Volume Reduction Surgery (Fishman et al., NEJM 2003)
NOTT/MRC — Continuous or Nocturnal Oxygen Therapy in Hypoxemic COPD (NOTT, Ann Intern Med 1980; MRC, Lancet 1981)
HOT-HMV Trial — Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation: A Randomized Clinical Trial (Murphy et al., JAMA 2017)
Practice Pulmonary questions on FirstPassPA
Turn this outline into retention. 7,700+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.